Li, Y.; Elakad, O.; Yao, S.; von Hammerstein-Equord, A.; Hinterthaner, M.; Danner, B.C.; Ferrai, C.; Ströbel, P.; Küffer, S.; Bohnenberger, H.
Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. Metabolites 2022, 12, 652.
https://doi.org/10.3390/metabo12070652
AMA Style
Li Y, Elakad O, Yao S, von Hammerstein-Equord A, Hinterthaner M, Danner BC, Ferrai C, Ströbel P, Küffer S, Bohnenberger H.
Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. Metabolites. 2022; 12(7):652.
https://doi.org/10.3390/metabo12070652
Chicago/Turabian Style
Li, Yuchan, Omar Elakad, Sha Yao, Alexander von Hammerstein-Equord, Marc Hinterthaner, Bernhard C. Danner, Carmelo Ferrai, Philipp Ströbel, Stefan Küffer, and Hanibal Bohnenberger.
2022. "Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma" Metabolites 12, no. 7: 652.
https://doi.org/10.3390/metabo12070652
APA Style
Li, Y., Elakad, O., Yao, S., von Hammerstein-Equord, A., Hinterthaner, M., Danner, B. C., Ferrai, C., Ströbel, P., Küffer, S., & Bohnenberger, H.
(2022). Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. Metabolites, 12(7), 652.
https://doi.org/10.3390/metabo12070652